CN108138234A - 治疗骨髓增生性障碍的方法 - Google Patents

治疗骨髓增生性障碍的方法 Download PDF

Info

Publication number
CN108138234A
CN108138234A CN201680034923.6A CN201680034923A CN108138234A CN 108138234 A CN108138234 A CN 108138234A CN 201680034923 A CN201680034923 A CN 201680034923A CN 108138234 A CN108138234 A CN 108138234A
Authority
CN
China
Prior art keywords
mutation
certain embodiments
sap
subject
myelofibrosis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680034923.6A
Other languages
English (en)
Chinese (zh)
Inventor
伊丽莎白·特雷胡布
理查德·M·杰克
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Promedior Inc
Original Assignee
Promedior Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Promedior Inc filed Critical Promedior Inc
Publication of CN108138234A publication Critical patent/CN108138234A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1716—Amyloid plaque core protein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/202—IL-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/212—IFN-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Pathology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Rheumatology (AREA)
  • Toxicology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Biotechnology (AREA)
  • Dermatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201680034923.6A 2015-04-15 2016-04-15 治疗骨髓增生性障碍的方法 Pending CN108138234A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562148005P 2015-04-15 2015-04-15
US62/148,005 2015-04-15
US201562218869P 2015-09-15 2015-09-15
US62/218,869 2015-09-15
PCT/US2016/027773 WO2016168612A1 (en) 2015-04-15 2016-04-15 Methods for treating myeloproliferative disorders

Publications (1)

Publication Number Publication Date
CN108138234A true CN108138234A (zh) 2018-06-08

Family

ID=57127338

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680034923.6A Pending CN108138234A (zh) 2015-04-15 2016-04-15 治疗骨髓增生性障碍的方法

Country Status (9)

Country Link
US (1) US20180318303A1 (https=)
EP (1) EP3283655A4 (https=)
JP (1) JP2018512164A (https=)
CN (1) CN108138234A (https=)
AU (1) AU2016248317A1 (https=)
CA (1) CA2983004A1 (https=)
HK (2) HK1250752A1 (https=)
RU (1) RU2017139122A (https=)
WO (1) WO2016168612A1 (https=)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021142963A1 (zh) * 2020-01-15 2021-07-22 上海众启生物科技有限公司 用于阿尔兹海默症自身抗体检测的蛋白抗原组合及其应用
CN113329752A (zh) * 2018-10-31 2021-08-31 斯坦林治疗公司 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法
CN114752575A (zh) * 2022-04-07 2022-07-15 内蒙古工业大学 一种nad+依赖性脱氢酶基因及其在提高辅酶q10产量中的应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9375485B2 (en) 2012-12-07 2016-06-28 Geron Corporation Use of telomerase inhibitors for the treatment of myeloproliferative disorders and myeloproliferative neoplasms
CN105792831A (zh) 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法
JP6852397B2 (ja) 2016-12-28 2021-03-31 株式会社島津製作所 分析用試料の調製方法および分析方法
ES2928773T3 (es) 2017-01-17 2022-11-22 Heparegenix Gmbh Inhibidores de proteína cinasas para fomentar la regeneración hepática o reducir o prevenir la muerte de hepatocitos
EP3589750B1 (en) 2017-03-01 2022-05-04 The Board of Trustees of the Leland Stanford Junior University Highly specific circular proximity ligation assay
DE102017107661A1 (de) * 2017-04-10 2018-10-11 Universität Rostock SH2B-Adapterprotein-3 für die Vorhersage einer Knochenmarkantwort und Immunantwort
WO2019169290A1 (en) 2018-03-02 2019-09-06 Allogene Therapeutics, Inc. Inducible chimeric cytokine receptors
US20200063214A1 (en) * 2018-07-31 2020-02-27 Geron Corporation Methods of identifying patients likely to benefit from treatment with a telomerase inhibitor
KR101962869B1 (ko) * 2018-08-02 2019-03-27 주식회사 우리메디칼 이미지 분석에 기반한 골수판독 지원 장치
JP7695885B2 (ja) 2019-02-12 2025-06-19 アンブルックス，インコーポレイテッド 抗体－ｔｌｒアゴニストコンジュゲートを含有する組成物、その方法、及び使用
BR112021017365A2 (pt) 2019-03-01 2022-02-01 Allogene Therapeutics Inc Receptores de citocina quiméricos constitutivamente ativos
EP3931208A1 (en) 2019-03-01 2022-01-05 Allogene Therapeutics, Inc. Chimeric cytokine receptors bearing a pd-1 ectodomain
WO2021041806A1 (en) 2019-08-30 2021-03-04 Allogene Therapeutics, Inc. Chimeric cytokine receptors comprising tgf beta binding domains
WO2021138391A1 (en) 2019-12-30 2021-07-08 Tyra Biosciences, Inc. Indazole compounds
JP2023514407A (ja) 2020-02-24 2023-04-05 アロジーン セラピューティクス，インコーポレイテッド 増強された活性を有するｂｃｍａ ｃａｒ－ｔ細胞
EP3900789A1 (en) 2020-04-23 2021-10-27 Universitätsklinikum Jena Pharmaceutical combination for the treatment of myeloproliferative neoplasms
CN113549597B (zh) * 2021-07-22 2022-03-25 浙江大学 一种人原发性骨髓纤维化细胞株及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072870A (zh) * 2004-10-27 2007-11-14 巴黎国立医院（Ah-Hp） 对真性红细胞增多症中jak2突变的鉴定
WO2010148234A1 (en) * 2009-06-17 2010-12-23 Promedior, Inc. Sap variants and their use

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105792831A (zh) * 2013-10-08 2016-07-20 普罗麦迪奥股份有限公司 用于治疗纤维化癌症的方法

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101072870A (zh) * 2004-10-27 2007-11-14 巴黎国立医院（Ah-Hp） 对真性红细胞增多症中jak2突变的鉴定
WO2010148234A1 (en) * 2009-06-17 2010-12-23 Promedior, Inc. Sap variants and their use

Non-Patent Citations (4)

* Cited by examiner, † Cited by third party
Title
A TEFFERI等: "CALR vs JAK2 vs MPL-mutated or triple-negative myelofibrosis: clinical, cytogenetic and molecular comparisons", 《LEUKEMIA》 *
ALESSANDRO M. VANNUCCHI等: "JAK2 allele burden in the myeloproliferative neoplasms: effects on phenotype, prognosis and change with treatment", 《THERAPUTIC ADVANCES IN HEMATOLOGY》 *
ALESSANDRO MARIA VANNUCCHI等: "Mutation-Enhanced International Prognostic Scoring System (MIPSS) for Primary Myelofibrosis: An AGIMM & IWG-MRT Project", 《BLOOD》 *
SRDAN VERSTOVSEK等: "Phase 2 Trial of PRM-15 1, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results", 《BLOOD》 *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113329752A (zh) * 2018-10-31 2021-08-31 斯坦林治疗公司 用白喉毒素-人白细胞介素-3缀合物与其它药剂组合治疗骨髓增生性肿瘤的组合治疗方法
WO2021142963A1 (zh) * 2020-01-15 2021-07-22 上海众启生物科技有限公司 用于阿尔兹海默症自身抗体检测的蛋白抗原组合及其应用
CN114752575A (zh) * 2022-04-07 2022-07-15 内蒙古工业大学 一种nad+依赖性脱氢酶基因及其在提高辅酶q10产量中的应用

Also Published As

Publication number Publication date
JP2018512164A (ja) 2018-05-17
CA2983004A1 (en) 2016-10-20
HK1250752A1 (zh) 2019-01-11
AU2016248317A1 (en) 2017-11-09
US20180318303A1 (en) 2018-11-08
EP3283655A1 (en) 2018-02-21
RU2017139122A (ru) 2019-05-15
WO2016168612A1 (en) 2016-10-20
RU2017139122A3 (https=) 2019-08-28
EP3283655A4 (en) 2018-12-05
HK1256036A1 (zh) 2019-09-13

Similar Documents

Publication Publication Date Title
CN108138234A (zh) 治疗骨髓增生性障碍的方法
JP7646221B2 (ja) 骨髄性悪性腫瘍の診断のための突然変異体カルレチクリン
JP6636914B2 (ja) 線維性癌の治療方法
KR20200005540A (ko) 암의 진단 및 치료 방법
EP2688907B1 (en) Dominant negative hsp110 mutant and its use in prognosing and treating cancers
JPWO2014017491A1 (ja) Ｃｅｐ５５遺伝子とｒｅｔ遺伝子との融合遺伝子
CN105431549A (zh) 癌症中的tert(端粒酶逆转录酶)基因启动子突变
AU2023254992A1 (en) CREBBP related cancer therapy
WO2004043232A2 (en) Methods for identifying risk of melanoma and treatments thereof
US7309760B2 (en) Repeat sequences of the CA125 gene and their use for diagnostic and therapeutic interventions
EP3969000B1 (en) Bcl-2 inhibitors for use in the treatment of a bcl-2 mediated cancer carrying the gly101val mutation
US20060216231A1 (en) Methods for diagnosing and treating tumors and suppressing cd promoters
CN110713544B (zh) 融合基因plekha6-ntrk3及其在lch中的应用
WO2004048546A2 (en) Methods for identifying risk of breast cancer and treatments thereof
WO2007115068A2 (en) Genetic variants in the indoleamine 2,3-dioxygenase gene
WO2005072053A2 (en) Novel nucleotide and amino acid sequences, and assays and methods of use thereof for diagnosis of colon cancer
HK40069679A (en) Methods for treating fibrotic cancers
WO2006076414A2 (en) Identification of phospholipase a2 as target in cancer treatment, with special emphasis on colorectal cancer and its mechanism of action
HK40058894A (en) Diagnostic methods and compositions for cancer immunotherapy
US20110092428A1 (en) Detecting and controlling abnormal hematopoiesis
JP2005224188A (ja) 骨代謝異常疾患に関連した転写因子に制御される遺伝子の選抜法とその利用
JPWO1999028459A1 (ja) Ｌｋｂ１遺伝子の変異に起因する疾患の検査方法、検査薬、および治療薬

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1256036

Country of ref document: HK

WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180608

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1256036

Country of ref document: HK